Celgene Phase II Revlimid MM data

CELG presented initial data from three Phase II trials of its Revlimid lenalidomide cancer compound. In a trial of Revlimid plus dexamethasone in 31 newly diagnosed patients with

Read the full 282 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE